Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allegra-D 24 Hour approval

This article was originally published in The Tan Sheet

Executive Summary

FDA clears Allegra-D 24 Hour Extended Release Tablets (fexofenadine HCl 180mg/ pseudoephedrine HCl 240mg) Oct. 19. The once-daily oral dose treats "seasonal allergy symptoms with nasal congestion in adults and children 12 years of age and older," FDA says. Aventis submitted the NDA for Allegra-D 24 Hour in December 2003, according to the firm's 1website...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS097419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel